Glucotrack (Nasdaq:GCTK) announced today that it completed the first-in-human clinical study of its continuous blood glucose monitor (CBGM). The study included participants with both type 1 and type 2 diabetes and began enrolling patients in early … [Read More...] about Glucotrack completes first-in-human continuous blood glucose monitor implant study
Main Content
Drug Tech
Today on Drug Delivery Business
- RenovoRx prices $12.1M offering
- Senseonics submits year-long CGM for CE mark
- Glooko, Innovation Zed partner on digital companion apps for injection therapy management
- Embecta stock rises on Street-beating Q1, patch pump continuation remains on track
- FDA warns of potential missed alerts with smartphone-connected diabetes devices
- Dexcom establishes direct presence in Italy with CGM launch, ends distro deal with Roche
- Are over-the-counter CGMs on track to be one-hit wonders?
Sponsored Content

Introduce New Drug Delivery Medical Devices with Lower Risk and Higher ROI
Manufacturing automation is crucial to achieving the precision, quality, and volume required in the medical device industry. Advanced robotics, AI, modular designs, and wireless technology offer the … [Read More...] about Introduce New Drug Delivery Medical Devices with Lower Risk and Higher ROI
Featured Posts

Senseonics submits year-long CGM for CE mark
By Sean Whooley
Senseonics (NYSE:SENS) announced today that it filed for CE mark for its Eversense 365 continuous glucose monitor (CGM) system. Eversense 365, the world's first 365-day CGM system, is the only CGM offering a year-long wear time. Market-leading, … [Read More...] about Senseonics submits year-long CGM for CE mark

Glooko, Innovation Zed partner on digital companion apps for injection therapy management
By Sean Whooley
Glooko and Innovation Zed today announced a strategic partnership to develop and deploy digital companion apps for injectable therapies. Palo Alto, California-based Glooko’s current platforms enable patients to share diabetes data with healthcare … [Read More...] about Glooko, Innovation Zed partner on digital companion apps for injection therapy management

Embecta stock rises on Street-beating Q1, patch pump continuation remains on track
By Sean Whooley
Embecta (Nasdaq:EMBC) shares ticked up before hours today on first-quarter results that came in ahead of the consensus forecast. Shares of EMBC rose 1.65% to $18.50 apiece in pre-market trading today. The Parsippany, New Jersey-based diabetes … [Read More...] about Embecta stock rises on Street-beating Q1, patch pump continuation remains on track

FDA warns of potential missed alerts with smartphone-connected diabetes devices
By Sean Whooley
The FDA today issued an alert around a safety concern regarding diabetes devices that rely on smartphones to deliver critical safety alerts. Devices like continuous glucose monitors (CGMs), insulin pumps and automated insulin dosing systems can … [Read More...] about FDA warns of potential missed alerts with smartphone-connected diabetes devices

Dexcom establishes direct presence in Italy with CGM launch, ends distro deal with Roche
By Sean Whooley
Dexcom (Nasdaq:DXCM) announced today that it plans to establish a direct presence in Italy, bringing its CGM technology to the country. The company plans to bring its continuous glucose monitoring (CGM) technology to Italy beginning in March 2025. … [Read More...] about Dexcom establishes direct presence in Italy with CGM launch, ends distro deal with Roche

Are over-the-counter CGMs on track to be one-hit wonders?
By drugdelivery
This medical device design expert’s family conducted a group trial of Dexcom Stelo and Abbott Lingo CGMs. By Steph Habif “Did you say you are now wearing a CGM?” my 78-year-old father asked me one day. “If so, what brand do you think is best for … [Read More...] about Are over-the-counter CGMs on track to be one-hit wonders?

Abbott leader, expert discuss stigma around diabetes management
By Sean Whooley
Abbott (NYSE:ABT) is launching a new initiative that takes a look at some of the stigmas and stereotypes that come with managing diabetes. With this initiative, the company wants to address misconceptions and stereotypes that weight heavily on the … [Read More...] about Abbott leader, expert discuss stigma around diabetes management

Abbott launches initiative to combat diabetes stigma
By Sean Whooley
Abbott (NYSE:ABT) today unveiled a new initiative addressing the biases and stigmas associated with diabetes management. The maker of the leading FreeStyle Libre continuous glucose monitor (CGM) platform launched the "Above the Bias" initiative … [Read More...] about Abbott launches initiative to combat diabetes stigma

Glucotrack completes first-in-human continuous blood glucose monitor implant study
By Sean Whooley
Glucotrack (Nasdaq:GCTK) announced today that it completed the first-in-human clinical study of its continuous blood glucose monitor (CBGM). The study included participants with both type 1 and type 2 diabetes and began enrolling patients in early … [Read More...] about Glucotrack completes first-in-human continuous blood glucose monitor implant study

Fractyl Health announces layoffs as it pivots to gene therapy
By Sean Whooley
Fractyl Health (Nasdaq:GUTS) is cutting nearly a fifth of its workforce as it streamlines resources and shifts focus toward certain therapies. The company, which develops therapies and procedures for treating obesity and type 2 diabetes, said it … [Read More...] about Fractyl Health announces layoffs as it pivots to gene therapy
In case you missed it
- Modular Medical takes step forward in CE mark process for insulin pump tech
- Trinity Biotech expects to submit ‘disruptive’ next-gen CGM to FDA in 2026
- Beta Bionics goes public with upsized $234.6M IPO
- BD to close infusion and syringe pumps facility in Israel
- Dexcom CEO says 2025 is ‘shaping up to be a good year’ with Stelo launch, GenAI integration
- Abbott Diabetes spurs growth with 22.7% uptick in CGM revenue, expects more insulin pump connectivity
- Dexcom inks glucose biosensor partnership with Life Time
- Medtronic says it has next-gen insulin pumps on the way, more to come from diabetes business
- Micron Biomedical raises $33M for needle-free drug delivery tech
- Analysts say Embecta is ‘heading in the right direction’ following patch pump discontinuation
- Aerosol drug delivery company Aerogen to expand in Ireland
- BD increases U.S. syringe, IV catheter manufacturing
- Insulet rolls out Omnipod 5 in more European countries
- Spirit Health to make new CGM available in UK
- Dexcom expects sales to grow 14% in 2025
Clinical Trials

Glucotrack completes first-in-human continuous blood glucose monitor implant study
Glucotrack (Nasdaq:GCTK) announced today that it completed the first-in-human clinical study of its continuous blood glucose monitor (CBGM). The study included participants with both type 1 and type 2 diabetes and began enrolling patients in early December 2024. Unlike traditional CGMs that measure glucose in interstitial fluid, the CBGM measures glucose levels directly from the […]

Trinity Biotech expects to submit ‘disruptive’ next-gen CGM to FDA in 2026
Trinity Biotech (Nasdaq:TRIB) announced new pre-pivotal clinical data supporting its next-generation continuous glucose monitor (CGM) system. Dublin, Ireland-based Trinity’s trial included 30 participants, primarily with type 1 diabetes. The company said it represents a significant milestone in its mission to deliver high-performance CGM technology. Its study highlighted the system’s signal quality, accuracy and more. The […]

Vivani Medical initiates first-in-human GLP-1-eluting implant study
Vivani Medical (Nasdaq:VANI) announced today that it initiated screening and enrollment for a first-in-human trial of its GLP-1 implant. The company initiated its LIBERATE-1 trial at two centers in Austrlalia. It will evaluate the miniature GLP-1 (exenatide) implant in obese and overweight subjects. This study follows FDA approval for an investigational new drug (IND) application for […]

MannKind reports positive data for inhaled insulin for children
MannKind today announced six-month results from its Phase 3 INHALE-1 study of Afrezza insulin inhalation powder in children. INHALE-1 looked at Afrezza in children and adolescents between 4-17 years of age. The company expects the data to support an upcoming request for a supplemental new drug application (sNDA) meeting with the FDA. It aims to […]

Glucotrack begins enrollment for first human trial of continuous blood glucose monitor
Glucotrack (Nasdaq:GCTK) announced today that it commenced patient enrollment for its short-term human clinical study. The study focuses on the company’s continuous blood glucose monitor (CBGM) and includes participants with both type 1 and type 2 diabetes. Rutherford, New Jersey-based Glucotrack expects data from the study in 6-8 weeks. Unlike traditional CGMs that measure glucose […]